Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.58 |
| ▸ | CA2 | P00918 | 10/20 | 0.58 |
| ▸ | CA9 | Q16790 | 10/20 | 0.58 |
| ▸ | CA5A | P35218 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA3 | P07451 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.58 |
| ▸ | LPL | P06858 | 7/20 | 0.56 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.56 |
| ▸ | F11 | P03951 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059437 | 0.85 | LIPG (0.57) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL1118853 | 0.81 | LIPG (0.56) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL21665984 | 0.81 | LIPG (0.53) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL15592879 | 0.81 | LIPG (0.56) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL23327430 | 0.81 | LIPG (0.53) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL17101700 | 0.78 | ESR2 (0.55) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL364006 | 0.77 | CA1 (0.71) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL15956361 | 0.77 | CA1 (0.41) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL6240959 | 0.77 | CA1 (0.44) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL171778 | 0.77 | LIPG (0.65) | CA1CA2CA9CA5ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-107074801-B | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclenones as antioxidant inflammatory modulators | 里亚塔医药公司 | 2021-11-05 | — | — | CN | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2014151367-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014124757-A1 | PYRROLOTRIAZINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2014-08-21 | — | — | WO | disclosed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2008110508-A1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INAPPROPRIATE IKK1 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007025575-A1 | O-HYDROXY- AND O-AMINO BENZAMIDE DERIVATIVES AS IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | CA1 4708/4885CA2 4122/4885CA9 2368/4885 |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | AKR1C3, AKR1C1, AKR1C2 | CA1 4568/4885CA2 4059/4885CA9 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.